Annals of Oncology

Papers
(The TQCC of Annals of Oncology is 1. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-09-01 to 2025-09-01.)
ArticleCitations
415P Comparison of cetuximab every 2 weeks versus standard once-weekly administration for the first-line treatment of RAS wild-type metastatic colorectal cancer among patients with left- and right-sid1033
Reply to the Letter to the Editor ‘AI-assisted personalized adjuvant chemotherapy in patients with pancreatic ductal adenocarcinoma’ by Y. Shimazu936
1246P A phase I dose-escalation study of mobocertinib (TAK-788), an oral tyrosine kinase inhibitor (TKI), in Japanese NSCLC patients873
212P A cohort study on the immunogenicity and safety of the inactivated SARS-CoV-2 vaccine (BBIBP-CorV) in patients with breast cancer: Does trastuzumab interfere with the outcome?697
123MO Monalizumab, cetuximab and durvalumab in first-line treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): A phase II trial693
588P Androgen changes after enzalutamide or abiraterone plus prednisone in men with castration-resistant prostate cancer (HEAT): Results from a randomised clinical trial666
111P A study on the relationship between tumor fusion burden (TFB) and tumor immune microenvironment586
118O Extended therapy with letrozole as adjuvant treatment of postmenopausal patients with early-stage breast cancer: A randomised, phase III trial of the Gruppo Italiano Mammella489
140P Benefit of adjuvant chemotherapy in luminal A-like early breast cancer in women aged 40 years or younger: Results of a national multi-institutional study460
1651P Phase I study of ramucirumab in combination with irinotecan plus cisplatin in patients (pts) with extensive-stage small cell lung cancer (ES-SCLC)434
P-111 Increased risk of pancreatic cancer among 141,387 diabetic patients treated with DPP-4 inhibitors analyzed with common data model422
801P Response to first-line platinum chemotherapy in microsatellite instability high (MSI-H) metastatic endometrial carcinoma418
839P Physician considered treatment attributes for third-line diffuse-large B-cell lymphoma treatment decision-making: Physician perspectives from a survey across Western Europe and US415
1803P The differences of TMB scores could be found in patients with different tumor types or pathological types394
31P Sulfhydryl groups in estrogen receptors394
P-332 Characteristic and clinical outcome of localized gastric cancer; real-world data389
Notice and Disclaimer363
P-362 Retrospective analysis of metastatic colorectal cancer based on clinical cancer registry data. Tumor biology, treatment, and outcome321
P-379 ARID1A as a prognostic biomarker in gastroesophageal cancer: A genomic database analysis312
1692P Thromboprophylaxis in high-risk oncology patients: Is it a safe and effective clinical decision-intervention?304
1520P Preferences on treatment decision making in sarcoma patients. Prevalence and associated factors: Results from the PROSa study301
1712P Safety and efficacy of influenza and pneumococcal vaccines in cancer patients on active therapy: A prospective study299
1483P Cell-free DNA dominant clone allele frequency associates with poor outcomes in advanced pancreatic cancer296
1482P Landscape of germline pathogenic variants beyond BRCA in pancreatic cancer patients294
404P Adolescent & young adult cancers (AYA): Experience from a large rural teaching hospital in South India260
1481P Predictors for 30-day readmission in patients with pancreatic cancer who had DNR code status248
50P Clinical characteristics, treatment patterns and outcomes of EGFR exon 20 insertion and other EGFR mutations in Korean aNSCLC patients236
431P Alveolar soft part sarcomas: A tertiary care Indian centre experience229
461P Spectrum of immune related adverse events (irAE) on treatment with checkpoint inhibitors and its association with survival: A real-world experience from India227
720P Integrative genomic analysis of matched primary and recurrent tumors reveals molecular characteristics of hepatocellular carcinoma with short-term recurrence220
1583P COVID-19 related risk in patients enrolled in early-phase clinical trials219
1164P Patient-reported outcomes in patients with advanced NSCLC before and during the COVID-19 pandemic in the German prospective CRISP Registry real-world cohort (AIO-TRK-0315)213
1186TiP EPONA, efficacy of osimertinib with platinum and pemetrexed in EGFR mutant non-small cell lung cancer patients bearing CNS metastasis, and have systemic progression but stable intracranial dis210
P-32 Risk factors for early recurrence after radical gastrectomy followed by adjuvant chemotherapy for stage II or III gastric cancer: A multicenter, retrospective study209
70P Genetic alterations and immune cell infiltration with potential impact on PD-(L)1 targeted treatment in various cancer entities: Biobank research project of the INFINITY registry198
P-404 Survival outcomes and prognostic factors in high risk locally advanced rectal cancers (LARC) undergoing concurrent capecitabine and long course radiation (Cape – RT) – results of a large cohort 196
651O Phase II trial of pembrolizumab (P) in combination with sEphB4-HSA (B4) in previously treated metastatic urothelial carcinoma (mUC)194
39P Clinical relevance of alterations in cancer (CRAC): A DB for selecting biomarkers for molecularly matched therapy in cancer patients194
677P Immunotherapy vs sunitinib as first-line treatment for advanced renal cell carcinoma in favourable risk patients: A meta-analysis of randomized clinical trials183
355P Butterfly glioblastoma: Treatment strategies and clinical outcome180
P-160 Primary gastrointestinal lymphoma in Latin American patients. A 10-year follow-up180
CN14 Cancer prevention awareness among Croatian AYA population178
CN28 Impact of serious illness care program to patients with hematopoietic stem cell transplantation on goals of care documentation and acute healthcare utilization171
P-173 Understanding the treatment algorithm of patients with advanced G2 gastroenteropancreatic neuroendocrine neoplasms: A single-institution retrospective analysis168
83TiP Clinical implications of clonal hematopoiesis mutations in patients with solid tumors166
P-177 Sex differences in chemotherapy-induced toxicities in gastric cancer patients165
Journal Information164
P-184 Prognostic value of mTOR expression and mismatch repair gene profile in advanced gastric and gastro-oesophageal cancer162
342P A signature of circulating microRNAs predicts the response to treatment with FOLFIRI plus aflibercept in metastatic colorectal cancer patients160
1012P Intratumoral immunotherapy with a novel TLR1/2/3 agonist, L-pampo, induces robust anti-tumor immune responses and enhances immune checkpoint blockade159
336P Prognostic and predictive value of Immunoscore in stage III colorectal cancer in the combined SCOT and IDEA-HORG studies159
137P Phase I dose-finding study of a novel anti-CTLA-4 antibody ADG116 as monotherapy in patients with advanced solid tumors154
202TiP A single-arm, open, multicenter and exploratory clinical study of fluzopari combined with apatinib in pts with platinum-sensitive relapsed ovarian cancer first-line treated with a PARP inhibito152
139P First-in-human (FIH), pharmacokinetic (PK) and pharmacodynamic (PD) study of IOA-244, a phosphoinositide 3-kinase delta (PI3Kδ) inhibitor, in patients with advanced metastatic mesothelioma, uveal152
O7-4 Ramucirumab plus FOLFIRI for RAS wild-type mCRC refractory to 1st-line treatment with anti-EGFR antibody: JACCRO CC-16147
37P Development of splice switching antisense oligonucleotides targeting midkine146
1295TiP Investigation of calcium electroporation (CaEP) therapy in malignant cutaneous and subcutaneous tumours: A non-randomized phase II clinical trial of a novel palliative therapy146
121P Treatment patterns and outcomes of recurrent/metastatic esophageal cancer: Real-world data145
52P HGCSG1901: A retrospective cohort study evaluating the safety and efficacy of S-1 and irinotecan plus bevacizumab in patients with metastatic colorectal cancer - Impact of single-heterozygous UGT1144
140P Lenvatinib + everolimus in mRCC that has progressed on immunotherapy: A real-world single center experience142
P-202 Topical diclofenac in prevention of capecitabine-associated HFS in patients with GI cancers: An exploratory subgroup analysis of the D-ToRCH study141
1076P Cancer cachexia associated with gut microbiota and clinical outcomes of patients with non-small cell lung cancer amenable to immunotherapy136
Title Page133
LBA41 Phase II study SECOMBIT (sequential combo immuno and target therapy study): 4-years OS data and preliminary biomarkers evaluation133
P-225 Appraising the potential causal relationships between gut microbiota and colorectal cancer: A two-sample Mendelian randomization analysis130
12P Any size of lymph node metastasis should be considered N1 in patients with cervical cancer130
11P Practice patterns and 90-day treatment-related morbidity in early-stage cervical cancer126
553P Real-world data on dostarlimab in post-platinum mismatch repair deficient (dMMR)/ microsatellite instability high (MSI-H) advanced/recurrent (A/R) endometrial cancer: Descriptive analysis of the 125
P-233 Modified FOLFIRINOX as neoadjuvant treatment in patients with borderline resectable and locally advanced pancreatic adenocarcinoma: A single-center study, updated with new data125
554P Does the type of hysterectomy affect the survival of patients with clinical IA endometrial cancer: A multicenter and retrospective study120
1627P Management of locally advanced rectal cancer during the COVID-19 outbreak: First results of a shift towards short course neoadjuvant radiotherapy118
1451MO In-situ immune markers predict nivolumab (N) +/-ipilimumab (I) efficacy in frontline metastatic clear cell renal cell carcinoma (mccRCC): Key ancillary analyses from the BIONIKK randomized tria118
MO38-2 Safety and pharmacokinetics (PK) of tusamitamab ravtansine (tusa) in Japanese patients (pts) with advanced solid tumors115
350P Primary prevention of chemotherapy-induced neutropenia in patients with advanced lung cancer in real-world research113
1642P Improve the conditions of lockdown may decrease anxiety among cancer patients during the COVID-19 pandemic113
1863P Incidence and predictors of severe adverse events during anti-PD-1 treatment113
1474P Prognostic value of PD-L1 in patients with metastatic renal cell carcinoma (mRCC) treated with antiangiogenic first line drugs (PROANG-SOGUG study)112
1133P Whole genome sequencing can classify diagnostically challenging tumors109
1485O Percutaneous uterine needle biopsy with microscopic and array-CGH analyses in patients with suspicious myometrial tumors on MRI: A prospective study107
373P Safety and efficacy of aumolertinib treatment in patients with advanced NSCLC harboring uncommon EGFR mutations: Cohort 2106
MO45-3 The efficacy of osimertinib in patients with EGFR-positive non-small cell lung cancer with malignant pleural effusion106
44P Breast cancer subtypes in Georgia: Higher frequency of triple-negative breast cancer compared to resource-rich areas105
51P Novel platform combines pathology and transcriptomics for a multi-scale analysis and visualization of the breast tumor heterogeneity104
P-42 How to improve outcome in high-risk stage III colon cancer with dMMR gene101
1352P A highly predictive blood-radiomics classifier in advanced NSCLC treated with immunotherapy99
470P Genomic landscape and its correlations with immunotherapy-related biomarkers in Chinese colorectal cancer patients97
1704P Multimodal approach to discover novel targets for antibody-drug conjugates by analyzing distinct expression patterns of frequent copy number aberration94
SY12-3 Precision medicine for esophageal cancer94
1233P EGFR-TKIs compared with radiotherapy for patients of stage IV lung adenocarcinoma with EGFR mutation94
105P CDK4/6 inhibitors in hormone receptor-positive, HER2-negative, locally advanced breast cancer (LABC): Biological and clinical activity, and post-surgical approaches94
SY01-1 Novel therapies and Immunotherapy for small cell lung cancer: Finally, some progress94
P-85 Treatment propensity and the feasibility of cisplatin plus gemcitabine in elderly patients aged ≥ 75 years with biliary tract cancer90
1366TiP Tepotinib + osimertinib for EGFR-mutant NSCLC with resistance to first-line osimertinib due to MET amplification (METamp): INSIGHT 290
P73-4 Experience with nivolumab in advanced metastatic gastric cancer88
1640TiP PECATI: A phase II trial to evaluate the efficacy and safety of lenvatinib in combination with pembrolizumab in pretreated advanced b3-thymoma (B3-T) and thymic carcinoma (TC)87
147P Chemo-immunotherapy with or without consolidative radiotherapy in extensive-stage small cell lung cancer: An initial report of clinical outcome and safety86
1224P Systematic review and meta-analysis of immunotherapy effectiveness for pretreated patients with non-small cell lung cancer harboring EGFR exon 20 insertions86
461P Molecular tumor profiling and matched molecular targeted treatment in metastatic young-onset colorectal cancer (YOCR)86
1225P The progression-free survival of the first-line EGFR-TKI is a strong prognosticator of the second-line osimertinib in non-small cell lung cancer (NSCLC) patients with EGFR-T790M mutation: A real85
1046P Homologous recombination deficiency (HRD) and genomic associations in non-small cell lung cancer (NSCLC) using a novel HRD signature (HRDsig)84
224P Adherence to adjuvant hormonal therapy in patients with localized breast cancer84
201P Metastatic and survival characteristics of de novo versus relapsed breast cancer in females aged>35-years-old: A nationwide multicenter study based on hospital population84
238P Budget impact analysis for the health care package by using MammaPrint in Belgium83
159P Pembrolizumab, SBRT, and immunomodulation for recurrent and/or refractory cervical or endometrial carcinoma82
1310MO Neoadjuvant platinum-based chemotherapy (NAPC) for metastatic penile squamous cell carcinoma (PSCC): An international, multicenter, real-world study81
ME07 New treatment strategy for hepatobiliary cancer80
1775P Prevalence of PD-L1 high expression in advanced urothelial carcinoma (aUC): Results from the PREVAIL prospective cohort study80
285P Reticulocyte hemoglobin equivalent as an early predictor of iron deficiency anemia in cancer patients79
CN26 Do patients with advanced lung cancer have more palliative care needs than patients with severe chronic obstructive pulmonary disease (COPD)?78
85P Safety and efficacy of atezolizumab (Atezo) + bevacizumab (Bev) in Japanese patients (pts) with unresectable hepatocellular carcinoma (uHCC): A prospective, multicenter, observational study (ELIXI77
852P Feasibility and safety of HiDAC in AML patients who have achieved CR with hypomethylating agents: Prospective study77
1638P Enzalutamide (enza) with or without leuprolide in patients (pts) with high-risk biochemically recurrent (hrBCR) prostate cancer (PC): EMBARK post hoc analysis by age76
2028TiP Phase I, non-randomised, open-label, multi-centre dose escalation trial of BI 764532 (DLL3/CD3 IgG-like T cell engager [TcE]) + ezabenlimab (anti-PD-1 antibody) in patients (pts) with small ce76
952P Prognostic implication of serum alpha-fetoprotein in patients with unresectable hepatocellular carcinoma treated with regorafenib76
169TiP Tocilizumab, ipilimumab, and nivolumab for the treatment of advanced melanoma, non-small cell lung cancer, or urothelial carcinoma75
464P Exome sequencing of ctDNA portrays the mutational landscape of patients with relapsing colon cancer and indicates new actionable targets75
596P Innovative multimodal deep-learning model for real-time prediction of recurrence in early-stage NSCLC75
589P Patient centricity in cancer: Overview past and current applications of patient reported outcomes74
554P Clinical outcomes of treating patients in prone compared to supine position for breast radiotherapy: A systematic review and meta-analysis73
709P The impact of antibiotic use on ICI plus chemotherapy versus chemotherapy in NSCLC patients with PD-L1 expression of 1% to 49%73
643P Resistance mechanisms and efficacy of first-line (1L) alectinib in patients (pts) with ALK-rearranged non-small cell lung cancer (ALK+ NSCLC): Second interim analysis of ALCURE73
699P Osimertinib combined with chemotherapy as first-line treatment in EGFR-mutant advanced NSCLC patients: The first real-world analysis in China72
781P Prognostic role of targeted amino acids as oncometabolites in acute lymphoblastic leukemia71
231P CT image-based artificial intelligence quantification of intratumoral heterogeneity for predicting treatment response to immunotherapy combined with anti-angiogenic drugs in hepatocellular carcin70
546P Multifaceted challenges in patient-centered oral cavity cancer care: An Asia-Pacific cross-sectional study with patients, caregivers, and healthcare professionals70
349P Predictive gene signature in primary prostate cancer associated with regional lymph-node metastasis using both mRNA and miRNA profiling70
259P Irinotecan liposome-based regimen in Chinese patients with advanced pancreatic cancer: A prospective, multi-center, observational real-world study70
415P Preliminary safety and efficacy results from phase II study pulsed radiotherapy with tislelizumab in patients with recurrent head & neck cancer69
483MO RNA-based multiplex polymerase chain reaction and sequencing to detect fusion genes in melanoma69
475P Impact of palliative care on the quality of life in advanced non-small cell lung cancer patients: A longitudinal study69
387P COL4A6 promotes tumor progression and chemoresistance in ovarian cancer by activation DDR1 pathway68
339P Comparison of stereotactic body radiation therapy(SBRT) and radical prostatectomy (RP) in high-risk/very high-risk prostate cancer: A large multi-center comparative analysis using propensity scor68
237P Radiotherapy with or without Immune checkpoint inhibitors and tyrosine kinase inhibitors in hepatocellular carcinoma with severe macrovascular invasion: A retrospective cohort study68
503P Retrospective evaluation of real-world experience and usefulness of implementing next-generation sequencing in clinical oncology: Insights from a developing Asian country67
344P Treatment intensification patterns in Asian patients with metastatic hormone sensitive prostate cancer (mHSPC)67
482MO Clinical usefulness of next-generation sequencing for metastatic or unresectable gastric cancer in molecular profiling-guided therapy era67
162P Efficacy of perioperative FLOT in gastric carcinoma and gastroesophageal junction carcinoma in achieving PCR: Retrospective analysis in a single institution experience67
217P The efficacy and safety of tislelizumab as adjuvant therapy in hepatocellular carcinoma with high-risk of recurrence after radical reaction66
178P KEYNOTE-859 update: Pembrolizumab + chemotherapy for advanced HER2-negative gastric or gastroesophageal junction (G/GEJ) cancer65
131MO Tislelizumab (TIS) plus chemotherapy (Chemo) vs placebo (PBO) plus chemo as first-line (1L) treatment of advanced gastric or gastroesophageal junction adenocarcinoma (GC/GEJC): Patient reported 65
501P Comparison between tissue and ctDNA for detecting tumor mutation burden (TMB) across solid tumors: A single centre study from India63
581P Informal caregiver mental health and time cost for stomach and pancreatic cancer care63
193P DCLK1’s kinase activity drives its pro-stemness effect in esophageal squamous cell carcinoma63
565P Prevalence of multi-drug resistant bacteria among neutropenic cancer patients and its association with 30-day mortality: A single centre study from a regional cancer centre63
517P Circulating tumor DNA dynamics to predict response to tyrosine kinase inhibitors in patients with advanced non-small cell lung cancer: An interim report62
1017P Updated safety and efficacy from the phase I study of givastomig, a novel claudin 18.2/4-1BB bispecific antibody, in claudin 18.2 positive advanced gastroesophageal carcinoma (GEC)62
1549TiP DeLLphi-303: Phase Ib first-line combination study of tarlatamab, a DLL3-targeting half-life extended bispecific T-cell engager (HLE BiTE®), with carboplatin, etoposide, and PD-L1 inhibition i62
CN16 Periodontal disease and cancer risk: A nationwide population-based cohort study61
557P Three-year update of real-world evaluation of ColonAiQ for colorectal cancer screening in asymptomatic individuals60
574P First-in-class PD-1/IL-2 bispecific antibody fusion protein IBI363 + bevacizumab (beva) in patients (pts) with advanced colorectal cancer (CRC): A phase I study59
727P Real-world efficacy and safety of cadonilimab in recurrent or metastatic cervical cancer: A multicenter retrospective analysis in China59
1011P Model-informed dose optimization of HFB200301, a TNFR2 agonist monoclonal antibody (mAb), in monotherapy and in combination with the anti-PD-1 mAb tislelizumab (TIS), in patients (pts) with adva58
761P Anti-angiogenic therapy in first-line treatment of low-grade serous ovarian cancer: Exploratory meta-analysis of the prospective AGO-OVAR 11/12/16 studies58
1748P A prospective, phase II study of tislelizumab administered in combination with eribulin and anlotinib for patients (pts) with advanced adult oft tissue sarcoma (TEASTS)57
1093P Preliminary biomarker analysis in the phase III PIVOTAL study: Evidence for the mechanism of action of daromun in melanoma57
138P Toward predicting immune checkpoint blockade response in oesophageal squamous cell carcinoma: Integrating tumour and blood characteristics57
1182P Determination of tumor PSMA expression in prostate cancer from blood using a novel epigenomic liquid biopsy platform57
256P Protein signature of tertiary lymphoid structure predicts efficacy of neoadjuvant chemotherapy in triple-negative breast cancer57
1632P Impact of androgen pathway inhibitors on cognitive function in elderly patients with metastatic prostate cancer: Results from the COG-PRO trial56
1248P Osimertinib (osi) after definitive chemoradiotherapy (CRT) in unresectable stage III epidermal growth factor receptor-mutated (EGFRm) NSCLC: LAURA China cohort analysis56
1863P Circulating biomarkers for risk stratification of cancer patients with chemotherapy associated febrile neutropenia55
1917P Updated survival and vaccine response from the NIPU trial: A randomised, phase II study evaluating nivolumab and ipilimumab with or without UV1 vaccination in patients with pleural mesothelioma55
211P GynePDX: A new platform of preclinical models for endometrial and ovarian cancers55
229TiP A phase II trial of a neural network-based treatment decision support tool in patients (pts) with refractory solid organ malignancies55
MO48-4 Efficacy and quality of life in blinatumomab treatment in patients with acute lymphoblastic leukemia: Systematic review54
1925MO Regomune study: A phase II study of regorafenib + avelumab in solid tumors. Results of the radioiodine-refractory differentiated thyroid cancer (RR-DTC)54
MO36-5 Non-familial prospective risk factors in predicting cancer of unknown primary: A systematic review and meta-analysis54
365P Radiotherapy treatment outcomes and treatment compliance of nasopharyngeal cancer patients in Sabah: A retrospective analysis52
MO60-4 Tryptophan is the prognostic factor in patients with unresectable pancreatic cancer52
622P A prognostic and immune infiltration analysis of CCL26 in pan-cancer52
268P Comparisons of on new-onset prostate cancer in type 2 diabetes mellitus exposed to the SGLT2I and DPP4I: A population-based cohort study51
331MO Comparing data distribution and prognosis of acute myeloid leukemia according to 5th WHO classification and international consensus51
201P A phase II study of serplulimab (a programmed death-1 inhibitor) with or without HLX04 (a bevacizumab biosimilar) for the treatment of advanced hepatocellular carcinoma50
MO20-3 Outcome of parameningeal head and neck rhabdomyosarcoma in adults: Kyushu Medical Oncology Group Study50
MO1-6 Steroid-resistant and refractory irAEs requiring additional immunosuppressants to steroids in advanced NSCLC patients50
375P Survival and prognostic factors of head and neck squamous cell carcinoma patients treated with either definitive CCRT or post operative CCRT with platinum-based chemotherapy in Rajavithi hospital50
213P Prognostic significance of absolute lymphocyte count in patients with metastatic renal cell carcinoma treated with first-line combination immunotherapies: Results from the International metastati49
195P Ferroptosis signatures in pancreatic ductal adenocarcinomas and their role in patient survival: A translational unsupervised clustering analysis49
MO68-4 A chemoproteoinformatics approach demonstrates that aspirin increases sensitivity to MEK inhibition by directly binding to RPS549
JS01-3 Optimizing cancer genome medicine in clinical practice in Japan49
402O A randomized phase III trial of site-specific therapy guided by the 90-gene expression assay versus empiric chemotherapy in patients with cancer of unknown primary49
505P Neoadjuvant PD-1 inhibitor (tislelizumab) plus platinum–etoposide in patients with limited-stage small cell lung cancer: A phase II trial49
MO6-5 Tumor microenvironment and clinical efficacy of atezolizumab plus bevacizumab for hepatocellular carcinoma49
451P The real-world efficacy and safety of anamorelin hydrochloride for Japanese unresectable non-small cell lung cancer patients with cachexia48
34P Social support as the mediator of the association between unmet needs and happiness among women with early breast cancer48
MO32-5 Impact of patient travel costs on disparities in precision oncology clinical trials47
MO43-6 UPRISE study: anxiety in patients with urothelial cancer in postoperative period -relation to patient demographics-47
MO5-1 Efficacy and safety of olaparib as a potential treatment for patients with pancreatic cancer: a systematic review47
MO23-5 A retrospective study of the management of distal lower extremity deep vein thrombosis in patients with cancer47
MO29-5 Correlation of COVID-19 pandemic and medical seeking behaviour in breast cancer patients at Siloam Hospitals Lippo Village47
P38-2 Efficacy and safety of lazertinib in the treatment of EGFR-mutated non-small cell lung cancer: a systematic review46
MO42-5 A phase 2 study of intrapatient dose escalation of bi-weekly FTD/TPI plus BEV for colorectal cancer (E-BiTS study)45
P11-9 Association of Charlson Comorbidity Index and safety of endoscopic resection gastric cancer patients: systematic review45
MO47-4 Neutrophil-lymphocyte ratio predicts prognosis in bone metastasis: meta-analysis of retrospective studies45
1707P Cancer drug prices in the US: Efficacy, innovation, clinical trial evidence, and epidemiology44
966P Diabetes therapy burden as proxy of impairment of immune checkpoint inhibitors efficacy44
SY19-5 Utility of circulating tumor DNA-based MRD monitoring following allogeneic transplantation in adult acute lymphoblastic leukemia44
SY24-KL1 Perioperative chemotherapy for gastric and gastroesophageal junction cancer, European perspective44
809P Mental and socioeconomic burden in endometrial and cervical cancer patients: A Swedish population-based study of survivorship44
60P A phase II trial of hepatic arterial infusion chemotherapy and bevacizumab in combination with toripalimab for advanced biliary tract cancers: Interim report44
1176P Planned drug holidays during immunotherapy in advanced and metastatic melanoma patients: A nation-wide study43
953P Tislelizumab plus regorafenib as second-line therapy for unresectable hepatocellular carcinoma (uHCC): A single-arm, phase II trial43
1036P A phase I/IIa first-in-human study of PM1003 (anti-PD-L1 x 4-1BB bispecific antibody) in patients with advanced solid tumors43
329P Pulmonary function and lung fibrosis up to 12 years after breast cancer radiotherapy43
1677P Pancreatic enzyme replacement therapy improves survival in patients receiving nab-paclitaxel plus gemcitabine as first-line treatment for advanced pancreatic adenocarcinoma43
907P Radiosensitivity signature in adenoid cystic carcinoma (ACC) of salivary glands origin is associated with ACC type II43
1673P Trajectories of immune-related serum proteins and quality of life in patients with pancreatic and other periampullary cancer: The champ study43
971P Effect of preoperative frailty on surgical outcomes following hepatic resection for elderly patients with hepatocellular carcinoma: A multicenter retrospective cohort study from China43
878P INHBA is overexpressed in HPV-negative oropharyngeal squamous cell carcinoma and contributes to an aggressive phenotype43
179P Molecular tumor board directed treatment for patients with advanced stage solid tumors: A case-control study42
1290TiP A phase II multicenter, open label, non-randomized study of neoadjuvant and adjuvant treatment with IPH5201 and durvalumab in patients with resectable, early-stage (II to IIIA) non-small cell 42
166P Metabolomic prediction of breast cancer treatment toxicities42
1122P Neutrophil/lymphocyte ratio and systemic inflammatory index as prognostic biomarkers in metastatic melanoma patients under immune checkpoint inhibitors: Could any of them be used?42
1398P Hepatotoxicity in patients (pts) with KRASG12C-mutated non-small cell lung cancer (NSCLC) treated with sotorasib after prior immunotherapy (IO)42
1152P Association of immune-related adverse events (irAE) requiring glucocorticoids (GCs) with outcome and biomarkers in advanced cutaneous malignant melanoma (CMM) treated with immune checkpoint inhi42
777P A prospective, single-arm, open-label study of camrelizumab, apatinib and nab-paclitaxel in patients with advanced cervical cancer41
526P Pharmacodynamic evidence for WEE1 target engagement in surrogate and tumor tissues from a phase I study of the WEE1 inhibitor ZN-c341
450O Initial monotherapy results of a phase I first-in-human study of ULK1/2 inhibitor DCC-3116 alone and in combination with MAPK pathway inhibition41
652O Dose-dense methotrexate, vinblastine, doxorubicin and cisplatin (dd-MVAC) or gemcitabine and cisplatin (GC) as perioperative chemotherapy for patients with muscle-invasive bladder cancer (MIBC): 40
251P First-line treatments and clinical outcomes for hormone receptor-positive, human epidermal growth factor 2-positive advanced or metastatic breast cancer: A systematic literature review40
SO-10 The prognostic role of microarchitecture in tumour-positive lymph nodes in oesophageal cancer patients: Results from the UK MRC OE02 trial40
646TiP A randomized phase III, factorial design, of cabazitaxel and pelvic radiotherapy in patients with localized prostate cancer and high-risk features of relapse: The PEACE 2 trial from Unicancer40
1042P Anti-PD1 (PD1) monotherapy or in combination with ipilimumab (IPI) after BRAF/MEK inhibitors (BRAF/MEKi) in BRAF mutant metastatic melanoma (MM) patients (pts)40
430P Real-world patient characteristics and treatment patterns in HR+/HER2+ metastatic breast cancer patients in 5 European countries40
12P The design and development of novel pentaranes: Paving the way to EMT inhibition in triple-negative breast cancer cells40
P-200 Mutational testing on liquid biopsies for treatment decisions in metastatic colorectal cancer – comparison of ddPCR and MassARRAY methods40
1747P Changes in global health status (GHS) in patients with advanced soft tissue sarcoma (STS) treated with first line palliative chemotherapy: Primary outcomes from the HOLISTIC study40
243P Targeting autophagy in tumor-associated macrophages effects the phenotype and tumor progression in urothelial carcinoma of bladder39
285O Prevalence of homologous recombination deficiency in ovarian, primary peritoneal, and/or fallopian tube cancer: Results from the international HALO study39
P-291 PIK3CA mutations in Tunisian patients with metastatic colorectal cancer: Patient stratification for targeted therapies39
1779TiP Phase II clinical study evaluating the efficacy and safety of disitamab vedotin in patients (pts) with HER2-expressing urothelial carcinoma (RC48G001)39
82P Obtaining microvesicles from T-lymphocytes using various methods of induction39
453P Routine DPYD mutation testing for patients receiving fluoropyrimidines for gastrointestinal (GI) cancers: Real world experience in a tertiary UK oncology centre39
1903P Tumor response by baseline metastases in patients (pts) with renal cell carcinoma (RCC) treated with lenvatinib (L) plus pembrolizumab (P) vs sunitinib (S): Post hoc analysis of the CLEAR trial38
Manufacture of adoptive cell therapies at academic cancer centers: scientific, safety and regulatory challenges38
2276P Regulation of major histocompatibility class-I gene methylation using DNA methyltransferase inhibitor and PD-L1 inhibitor in triple-negative breast cancer38
309P Antineoplastic (ANP) therapies (Tx) after alpelisib (ALP) or placebo (PBO) + fulvestrant (FUL) in patients (Pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-neg37
1753P Cost-effectiveness (CE) of nivolumab (NIVO) as adjuvant treatment of muscle invasive urothelial carcinoma at high risk of recurrence (MIUC-HR) in France37
219P Accuracy of MRI to assess response after neoadjuvant chemotherapy according to immunohistochemical breast cancer subtypes: A systematic review and meta-analysis37
1824P Treatment patterns among novel hormonal therapy-experienced patients with metastatic castration-resistant prostate cancer37
742P Survival in patients (pts) with advanced ovarian cancer (AOC) changes with cumulative number of risk factors (RFs): A US real-world (RW) analysis37
27P Plasma-derived exosomes as biomarkers for therapy monitoring in head and neck cancer patients treated with surgery and (chemo)radiotherapy37
P-285 Q-TWiST analysis for pembrolizumab plus chemotherapy versus chemotherapy as first-line treatment for patients with advanced esophageal cancer in the KEYNOTE-590 study37
109P A novel, comprehensive glimpse at NY-ESO-1 expression, mRNA to protein translation, & potential impact on clinical studies37
995P Real-world treatment patterns, survival and costs in advanced hepatocellular carcinoma (aHCC) in Ontario, Canada36
1608P Albumin-myosteatosis gauge as a prognostic factor in patients with advanced pancreatic cancer undergoing first-line chemotherapy36
1296P Neoadjuvant camrelizumab and apatinib in patients with resectable non-small-cell lung cancer: One-year update from a phase II trial36
1593MO Combined early palliative care in patients with non small cell lung cancer: A randomised controlled trial in Chongqing, China36
1024MO Interpretable AI-identified spatial tumor microenvironment (TME) neighborhoods associate with severe immune-related adverse events (irAE) and progressive disease (PD) in patients with melanoma 36
1310P Loratadine: A potential game-changer in lung cancer treatment with improved survival outcomes36
0.16064691543579